

REMARKS

Reconsideration and allowance are respectfully requested.

Claims 1-8 and 10-14 are pending. The amendments are fully supported by the original disclosure and, thus, no new matter is added by their entry. Amendment of the specification and submission of a corrected Sequence Listing respond to the Examiner's objection and requirement on page 2 of the Office Action. Amendment of the claims respond to the Examiner's objection on pages 4-5 of the Office Action.

Claims 1-8 and 10-14 were rejected under Section 112, second paragraph, as being allegedly indefinite. Applicants traverse.

The Examiner's suggestions for amending the claims to correct informalities are gratefully acknowledged. Adoption of some of his suggestions moots certain rejections.

The definition of α -fluoralkylated amino acid is found on pages 405 of the specification.

Applicants request withdrawal of the Section 112, second paragraph, rejection because the pending claims are clear and definite.

Having fully responded to all of the pending objections and rejections contained in this Office Action, Applicants submit that the claims are in condition for allowance and earnestly solicit an early Notice to that effect. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: /Gary R. Tanigawa/

Gary R. Tanigawa

Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100